Lupin has informed about submission of a Press Release as regards completion of the US FDA inspection carried out at the Company's Torapur manufacturing (API) facility between September 16 to September 20, 2019. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.